Study ID: COG ANBL0032
Description:
Phase III Randomized Study of Chimeric Antibody 14.18 (Ch14.18) in High Risk Neuroblastoma Following Myeloblative Therapy and Autologous Stem Cell Rescue
Location:
Sioux Falls Region
Principal Investigator:
Kayelyn Wagner MD
Disease:
NBL (Neuroblastoma)
Stage:
Phase III
Status:
Active - Open to Accrual
For more information, call or email Bismarck Clinical Research at (701) 323-5760, Fargo and Bemidji Clinical Research at (701) 234-5890, or Sioux Falls Clinical Research at (605) 328-1368.
Back to Clinical Trials list